RAFAEL
DELGADO VÁZQUEZ
Profesor titular de universidad
Instituto de Investigación Sanitaria Hospital 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Hospital 12 de Octubre (12)
2024
-
Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood-Brain Barrier-Permeable Ebola Virus Entry Inhibitors
Journal of Medicinal Chemistry, Vol. 67, Núm. 18, pp. 16381-16402
-
HIV-1 Reverse Transcriptase Error Rates and Transcriptional Thresholds Based on Single-strand Consensus Sequencing of Target RNA Derived From In Vitro-transcription and HIV-infected Cells
Journal of Molecular Biology, Vol. 436, Núm. 22
2023
-
Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis
Frontiers in Cellular and Infection Microbiology, Vol. 13
-
Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines
Journal of Medical Virology, Vol. 95, Núm. 1
-
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
Advanced Science, Vol. 10, Núm. 34
-
Immune Response Against SARS-CoV-2 Infection and Vaccination in a CD8α-Deficient Patient
Journal of Clinical Immunology
-
N′-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile
Journal of Medicinal Chemistry, Vol. 66, Núm. 8, pp. 5465-5483
-
Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
Frontiers in Immunology, Vol. 14
2022
-
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
Frontiers in Immunology, Vol. 13
-
First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 40, Núm. 10, pp. 546-549
-
Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
The Journal of infectious diseases, Vol. 227, Núm. 1, pp. 35-39
2020
-
Prevalence and Clinical Manifestations of Congenital Cytomegalovirus Infection in a Screening Program in Madrid (PICCSA Study)
Pediatric Infectious Disease Journal, Vol. 39, Núm. 11, pp. 1050-1056